Dr. Jay Bhaumik’s career in the pharmaceutical sector, including serving as Chairman of Thesis Compounding Pharmacy, has exposed him repeatedly to the clinical reality that the drug that works well for one patient can fail or even cause harm in the next, despite an identical diagnosis. Medicine has long organized itself around what is typical, calibrating doses, formulations, and treatment protocols to a population norm.
As statistically convenient as the average patient model is, it describes practically no one in exact terms. Uniform treatment protocols continue to persist because they are easier to manufacture and prescribe at scale than individualized alternatives. They are also easier to regulate. Convenience cannot be considered equal to clinical accuracy, and the gap between the two appears in outcomes that standard dosing will not anticipate.
When Genetic Variation Determines Drug Response
Pharmacogenomics has quietly dismantled the assumption that a given drug behaves consistently from patient to patient. Genetic differences in the enzymes responsible for metabolizing medications can account for substantial swings in how a drug is processed and cleared from the body, with researchers estimating that an individual’s genetic makeup explains a wide range of the variability seen in drug disposition and effect.
A medication metabolized too slowly can accumulate to toxic levels. Metabolized too quickly, it may never reach a therapeutic threshold at all. Two patients prescribed identical doses of the same drug for the same condition can, therefore, experience entirely different outcomes, one achieving relief and the other absorbing side effects with no corresponding benefit. Standard dosing was never designed to account for such biological divergence, because it was built around population averages.
The Problem with Standard Dosing Across Age and Organ Function
As a singular factor, age reshapes how a body handles medication in ways that a uniform dosing chart can never capture. Declining renal and hepatic function slows the clearance of many drugs in older adults, and age-related changes in pharmacokinetics commonly mean that a standard adult dose behaves like a considerably larger one once it reaches an aging liver and kidneys.
Reduced glomerular filtration prolongs drug half-lives, increasing the risk of accumulation and toxicity when dosing decisions ignore organ function. Children present the inverse challenge, requiring calculations based on weight or body surface area instead of a fixed adult reference point.
“The pharmaceutical industry builds products for the middle of the bell curve, but patients don’t live in the middle of the bell curve. They live at every point along it, and dosing that ignores age, organ function, and body composition is dosing that’s guessing,” says Dr. Jay Bhaumik.
Formulation Barriers That Standard Dosing Ignores
Even when a dose calculation is correct on paper, the commercially available form of a drug can make accurate administration nearly impossible. Splitting tablets to approximate a pediatric or geriatric dose introduces variability that compounded liquid suspensions were specifically shown to eliminate, since manipulating solid dosage forms produces measurable underdosing compared with formulations built to the patient’s actual required strength.
Swallowing difficulties, feeding tubes, and even documented sensitivities to dyes or preservatives compound the problem further, leaving patients whose bodies cannot tolerate the standard formulation with no commercially manufactured alternative.
Dr. Bhaumik points out that formulation, not just dose, can be where individualized care breaks down before it ever reaches the patient.
“A correct dose in the wrong formulation still fails the patient. Getting the number right on a chart means nothing if the child can’t swallow the tablet or the caregiver can’t accurately split it,” says Dr. Bhaumik.
The Cost of Uniform Treatment in Adverse Events
Mismatched dosing carries consequences that surpass a missed therapeutic effect. Adverse drug reactions are a persistent driver of hospital admissions, with polypharmacy and advanced age independently associated with a substantially higher likelihood of an emergency hospitalization caused by a drug reaction.
Patients managing multiple chronic conditions and taking several medications simultaneously face compounding risk, since standard doses calculated in isolation seldom account for how drugs interact once combined in an individual’s actual physiology.
Preventable hospitalizations that fall into this category represent a direct, measurable cost of treating dosing as a fixed variable instead of a patient-specific calculation. Every uniform dose that ignores comorbidity, organ function, and concurrent medications carries a quiet risk that population-level clinical trials were not designed to identify.
Chronic Disease Management and the Case for Personalization
Chronic disease management will expose the limitations of standardized treatment most clearly, because these are the patients cycling through dose adjustments or formulation changes and medication combinations over years as opposed to weeks. Regulators have increasingly acknowledged that most medical treatments are designed for the average patient.
The methodology succeeds for many but leaves a meaningful subset of patients underserved or actively harmed by the same protocol. Hormone therapy, as well as pain management and autoimmune conditions, may require ongoing titration that a fixed commercial dose cannot accommodate.
Patients managing these conditions long-term typically need a treatment plan that shifts as their disease, weight, and organ function shift alongside it, something a single manufactured strength was never built to do.
“Chronic disease doesn’t hold still, thus the treatment plan cannot either. A patient’s needs today aren’t necessarily their needs in eighteen months, and a static, one-size prescription eventually stops matching the person taking it,” says Dr. Bhaumik.
What Individualized Treatment Actually Requires
No part of this suggests that standardized medications have zero value. In fact, they remain foundational to modern pharmaceutical care and the appropriate choice for a substantial share of patients. A meaningful subset of patients falls outside the standard entirely, sometimes due to genetics, age, organ function, formulation intolerance, or the compounding complexity of chronic illness.
To close the gap, clinicians, pharmacists, and manufacturers must be willing to treat dosing and formulation as variables, not constants. Patients for whom standard treatment is not effective are a predictable and recurring segment of every population that a drug is meant to serve. Medicine’s primary task becomes building the flexibility to reach them.
